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ABSTRAK
Pendahuluan: Saat ini diketahui bahwa inflamasi berperan besar dalam patogenesis kanker. Proses inflamasi mengaktifkan sistem 
imun melalui mediator pro inflamasi dan selanjutnya memicu transformasi sel menjadi ganas. Beberapa tumor atau kanker dikaitkan 
dengan infeksi kronis, seperti virus hepatitis B dan C (karsinoma hepatoseluler), human papilloma virus (kanker serviks), Helicobacter 
pylori (kanker lambung dan limfoma), dan prostatitis (kanker prostat). Banyak penelitian yang telah mengkaji manfaat aspirin untuk 
pencegahan dan terapi kanker atau tumor. Tujuan: Tulisan ini bertujuan untuk memaparkan keterkaitan antara inflamasi dengan 
kejadian kanker, sehingga penggunaan aspirin sebagai agen antiinflamasi merupakan pilihan yang rasional dalam terapi dan pencegahan 
kanker. Aspirin potensial untuk kemoprevensi berbagai jenis kanker. Mengingat efek samping aspirin cukup besar, maka pemberian 
aspirin tidak dimaksudkan sebagai terapi rutin untuk mencegah kejadian kanker.
Kata kunci: inflamasi, kanker, aspirin
ABSTRACT
Introduction: inflammation has been shown to play a major role in the pathogenesis of cancer. Inflammatory process activates the immune system 
through pro-inflammatory mediators and subsequent triggers transformation into malignant cells. Some tumors or cancers has been associated with 
chronic infections, such as hepatitis B and C viruses (hepatocellular carcinoma), human papilloma virus (cervical cancer), Helicobacter pylori (gastric 
cancer and lymphoma), and prostatitis (prostate cancer). A considerable study have investigated the benefits of aspirin for the prevention and treatment 
of cancer or tumors. Objectives: This paper aims to describe the relationship between inflammation and cancer incidence, so that use of aspirin as an 
anti-inflammatory agent is a rational choice in the treatment and prevention of cancer. Conclusion: Aspirin potential for chemoprevention of various 
types of cancer. Considering the high risk of side effects of aspirin, aspirin is not intended as a routine therapy to prevent the occurrence of cancer.
Keywords: inflammation, cancer, aspirin
INTRODUCTION
Cancer is a genetic disorder involving the failure 
of  apoptosis and DNA repair (Zingde, 2001). DNA 
damage is caused by various factors such as radiation, 
carcinogenic chemicals, and infection, through the 
mechanism of  tissue damage due to inflammation. 
Chronic inflammation in a cell or tissue activates 
immune cells to produce pro-inflammatory mediators 
such as cytokines, chemokines, adhesion molecules and 
free radicals. Inflammatory mediators will intervene 
so that the normal cells transform into malignant cells 
which capable of  invasion and metastasis (Deng et 
al., 2012).
A great body of research have been done on aspirin 
use, an anti-inflammatory analgesic, in the treatment 
of  cancer. The results of  the studies showed that the 
use of  aspirin and other NSAIDs in several cancers 
has been shown to be beneficial (to be discussed in the 
following section), thus, supporting the effectiveness 
of  aspirin for cancer therapy and chemoprevention in 
certain risk of  population.
LITERATURE REVIEW
Correlation between Cancer and Inflammation
A number of studies has shown that inflammation 
is directly associated with incidence of  cancer. Some 
medical conditions have been reported to be associated 
with the incidence of  cancer including hepatitis B and 
C viruses (hepatocellular carcinoma), human papilloma 
virus (cervical cancer), and Helicobacter pylori (gastric 
cancer and lymphoma) (Trinchieri, 2011; Zhu et 
al., 2012). The inflammatory microenvironment is 
similar to that of  tumor in which the inflammatory 
component is also present in the micro environment of  
neoplastic tissues (Zhu et al., 2012). In an inflammatory 
microenvironment, reactive oxygen species (ROS) and 
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reactive nitrogen species (RNS) are also present, which 
are the physiological mechanism of  immune cells to the 
inflammatory stimulation (Trinchieri, 2011), as well as 
an indicator that cells undergo oxidative stress (Moossavi 
& Bishehsari, 2012). Increased ROS and RNS cause 
genetic instability and impaired DNA repair through 
post-translational modification of  tumor suppressor 
genes such as p53 and PRB, triggering transformation 
into malignant cells (Deng et al., 2012).
Some of  the things that show the link between 
inflammation and cancer include:
1.  Hematopoietic cells, epithelial cells, endothelial 
cells, fibroblasts, lymphocytes, dendritic cells, mast 
cells, and stromal cells entering into the tissues are 
the beginning of  cancer progression. These various 
immune cells are activated by chronic infections 
such as Hepatitis B virus infection (HBV), Human 
Papilloma Virus (HPV), H. pylori, and Eipstein 
Barr Virus (EBV) (Deng et al., 2012), triggering 
inflammation by secreting pro-inflammatory 
factors. Inflammation also causes obstacles to the 
anti-tumor immune response and then be able to 
determine the response of  tumor cells to drug 
therapy (Deng et al., 2012)
2.  Nuclear factor kappa-B (NF-κB), transcription 
factors in eukaryotic cells that function in 
gene promoter for inflammation (Trinchieri, 
2011), the immune response, and antiapoptotic 
mechanisms present in cancer cells (Xiong et al., 
2003). A transcription factor that will stimulate 
the production of  proinflammatory cytokines 
(Trinchieri, 2011), activation of  oncogenes in 
malignant cells (Moossavi & Bishehsari, 2012) 
and plays an important role in tumor cell survival 
(Chattopadhyay et al., 2012).
3.  Signal transducer and activator of  transcription 3 
(STAT3), a factor that plays a role in maintaining 
tumor cell survival, proliferation and spread of  
tumor cells, is expressed in cancer cells. Moreover, 
STAT3 also maintain the cancer cells alive by 
inhibiting apoptosis through p53 suppression and 
controlling pro-angiogenic factors and metastasis 
(Trinchieri, 2011).
4.  The inflammatory receptors in the cytoplasm 
activate caspase 1, and then stimulate the 
production of  interleukin (IL) -1β and IL-18 as 
pro-inflammatory cytokines (Trinchieri 2011; 
Dinarello, 2010).
5.  The cyclooxygenase-2 (COX-2) enzyme expressed 
cancer, which in conditions of  normal colonic 
epithelium the enzyme was not expressed (Moossavi 
& Bishehsari, 2012). In addition, it was found that 
prostaglandin levels were significantly higher in 
cancer tissue than in normal tissue (Holmes et al., 
2010).
Based on these explanation, it is obvious 
that malignancy is directly due to the involvement 
of  the immune system, cytokines, chemokines, and 
transcription factors, which together form an “orchestra” 
in the pathogenesis of  tumor (Zhu et al., 2012). Various 
immune cells in the inflammatory process would 
stimulate the production of  cytokines and chemokines 
which play a major role in the pathogenesis of  cancer 
(Deng et al., 2012). The phenomenon is more common 
in cells having abnormal or premalignant lesions. 
Chronic activation of  the immune system, stromal 
fibroblasts, mesenchymal cells and vascular backers 
in premalignant lesions causing premalignant lesions 
become larger, because of  the involvement of  a variety 
of  immune cells is immunosuppressive. Therefore, this 
situation can be considered as wounds that do not 
heal, and triggers the progression of  cancer (Shiao et 
al., 2011).
Anti Inflammation Agent, Aspirin, in Cancer 
Chemoprevention
Aspirin is the prototype of  non-steroidal anti-
inflammatory (NSAID). Unlike other NSAIDs 
reversibly inhibiting enzymes, aspirin inhibits COX 
enzymes irreversibly. This is because aspirin causes 
acetylation of  a serine residue at the terminal carbon 
group of  the COX enzyme. Thus, to produce a new 
prostanoid synthesis requires other COX enzyme (Vane 
and Botting, 2003). This process is important due to 
its association with the effect of  aspirin, in which the 
duration of  the effect is highly dependent on the rate 
of  turn over COX enzymes (Roy, 2007).
An improved understanding that chronic 
inflammation triggers cancer incidence encourages 
researches aiming at determining the efficacy of  the 
use of  many anti-inflammatory drugs to prevent 
the incidence of  cancer. The concept of  cancer 
chemoprevention using aspirin showed that the use 
of  long-term aspirin at the of  at least 75 mg/day can 
prevent the incidence of  cancer and decrease the number 
of  mortality (Rothwell et al., 2010; Rothwell et al., 2011; 
Rothwell et al., 2012a), as well as reduce the possibility 
of  metastasis if  given right after cancer diagnosis is 
established (Rothwell et al., 2012b). Reduction in the 
number of  mortality from cancer has been assumed 
to be due to repairs premalignant lesions, which are 
in large amounts in colon disorder such as 
inflammatory bowel disease (IBD) and colorectal 
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associated with chronic inflammation in a variety of  
solid organs (Antonoff  & D’Cunha, 2011). Repairs 
to premalignant lesions in turn will be able to reduce 
the risk the development of  normal cells into cancer 
cells.
Studies on Aspirin in Cancer Prevention
a. Aspirin and Colorectal Cancer
Colorectal cancer is the most common malignancy 
studied related to the use of  aspirin for the prevention 
and treatment of  cancer. Short-term use of  aspirin (less 
than 3 years) does not significantly reduce the risk of  
colorectal cancer (Rothwell et al., 2012a). Low-dose 
aspirin (75mg/day) effectively prevention of  cancer 
incidence after 5 years (odds ratio [OR] 0.78; 95% 
confidence interval [CI]=0.65 to 0.92, p=0.004). The 
preventive effect of  the use of  aspirin on cancer has 
been shown after one year and increase with longer 
use (Din et al., 2010). An observation for 20 years 
found a lower cancer mortality by 20% with aspirin 
therapy compared with no aspirin therapy (Rothwell 
et al., 2011).
As chemoprevention, aspirin and other NSAIDs 
are effective for preventing the incidence of  colorectal 
cancer mortality in patients simultaneously Lynch 
syndrome (Barton, 2012), adenoma (Manzano & Perez-
Segura, 2011), and familial adenomatous polyposis 
(Chan, 2011). Aspirin also been proven to prevent 
cancer in addition to colorectal cancer associated with 
Lynch syndrome, such as endometrial cancer, brain, 
small intestine, pancreas, ureter, stomach, and kidney 
(Barton, 2012).
b. Aspirin and Gastric Cancer
A cohort study showed that regular use of  aspirin 
is associated with a lower risk of  gastric cancer of  the 
distal (HR 0.73; 95% CI=0.61-0.89; P trend 0.009), 
compared with no aspirin (HR 1:00; 95% CI= 0.81-
1:24; P trend=0.99 ) (Epplein, et al., 2009). Other studies 
showed similar results, in which aspirin lowers the risk 
of  gastric cancer compared with no aspirin, with an 
OR of  0.7 (95% CI=0.6-1.0). The risk of  gastric cancer 
decreased with increasing frequency of  aspirin (Akre 
et al., 2001).
Researchs from 3 case-control study of  gastric 
cancer had a RR of  0.67 (95% CI=0:56-0.80), from 4 
study cohort of  0.93 (95% CI=0.82-1:05), and to the 
whole study of  0.84 (95% CI=0.76-0.93) (Bosetti et 
al., 2009). Continuos use of  aspirin also determine the 
final outcome. A regular aspirin use (OR 0:57 (95% 
CI=0:44-0.74)) reduces the risk of  gastric cancer, is 
greater than the irregular (OR 0.84 (95% CI=0.66-1:07)). 
Irregular use of  aspirin had the same result without 
aspirin therapy (Wang et al., 2003).
c. Aspirin and Lung Cancer 
Consuming aspirin regularly after resection of  
lung cancer can improve survival rate by 5% (p=0.05) 
(Fontaine et al., 2010). Routine use of  aspirin in patients 
with lung cancer had RR of  0.70 (95% CI=0:56-0.88) 
of  two case-control studies, 0.96 (95% CI=0.91-1:02) 
of  6 study cohort, and 0.94 (95% CI=0.89-1.00) for 
the entire study (Bosetti et al., 2009). A meta analysis 
study found that the value of  RR on six case-control 
studies of  0.63 (95% CI=0:47-0.86), in the eight study 
cohort of  0.78 (95% CI=0.62-0.98), whereas for the 
overall study of  0.79 (95% CI=0.66-0.95). For lung 
cancer, the type of  small-cell has a better prognosis (RR 
0:48; 95% CI=0:30-0.75) compared with the type of  
non-small cell (RR 0.66; 95% CI=0:56-0.79) (Khuder 
et al., 2005).
d. Aspirin and Breast Cancer  
Breast cancer with positive estrogen receptor 
(ER +), can be treated with anti estrogen. However, 
when the estrogen receptor is negative (ER-), the use 
of  anti estrogen is not effective, so that conventional 
therapies such as chemotherapy and radiotherapy were 
still an option. In vivo study by Chattopadhyay, et 
al. (2012) demonstrated that the use of  aspirin in ER- 
breast cancer is effective in controlling the growth of  
cancer cells characterized by the reduction of  cancer 
size whereas in vitro studies found that it inhibited 
tumor cell proliferation (due to inhibited cell cycle), 
increased apoptosis, decreased expression of  NF-κB, 
decreased thioredoxin reductase activity, and increased 
concentration of  ROS in tumor cells. Holmes, et al. 
(2010) found that administration of  aspirin for one 
year after the diagnosis of  breast cancer can reduce 
the risk of  metastasis, cancer mortality, and death due 
to other causes. The benefits of  aspirin therapy is not 
dependent on the stage of  the cancer, menopausal 
status, body mass index, and estrogen receptor status 
(ER+ or ER-).
e. Aspirin and Other Cancer 
In cases of  esophageal cancer, the RR of  two 
case-control studies was shown to be 0:41 (95% CI=0:29 
to 0:57), from 4 study cohort of  0.83 (95% CI; 0.70-
0.98), and for the total study was 0.72 (95% CI=0.62-
0.84) (Bosetti et al., 2009). A regular aspirin therapy 
is more effective and cost-effective compared with no 
aspirin at 0:19 quality-adjusted life years (QALY). The 
combination of  aspirin therapy and surveillance using 
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an endoscope generated a 0:27 QALY compared with 
no aspirin therapy, and save US $ 13,400 with the cost 
effectiveness ratio of  49 600 US $/QALY. This therapy 
model is highly dependent on the age and the delay in 
starting aspirin therapy (Hur et al., 2004).
Researches on pancreatic cancer showed the 
value RR in two case-control studies were 1.00 (95% 
CI=0.72-1:39) and from 5 cohort studies accounted 
for 0.96 (95% CI=0.92-1:01). The limited number of  
research on pancreatic cancer caused no conclusive 
evidence for the relationship between the use of  aspirin 
and the incidence of  pancreatic cancer (Bosetti et al., 
2009).
Aspirin’s administration to Hodgkin lymphoma 
has been shown to reduce the risk of  incidence of  
Hodgkin’s lymphoma with OR 0.60 (95% CI=0.42-
0.85), whereas the use of  NSAIDs non aspirin couldn’t 
reduce the risk of  this cancer, with an OR 0:07 (95% 
CI=0.73-1.30) (Chang et al., 2004). For non-Hodgkin 
lymphoma, pooled RR of  four case-control studies of  
0.98 (95% CI=0.85-1.14), from 2 cohort studies was 
at 1:08 (95% CI=0.78-1.51), while for the overall study 
the value of  RR was 1.00 (95% CI=0.88-1.14) (Bosetti 
et al., 2009).
The different results were obtained for 
malignancy of  the prostate and kidney. Relative risk 
of  prostate cancer, the value of  pooled RR of  five case-
control studies was 1.02 (95% CI=0.90-1.16), from 
10 cohort studies were 0.97 (95% CI=0.94-1.01) and 
from total study 0.98 (95% CI=0.95-1.01) respectively. 
The finding shows that the regular administration of  
aspirin did not lower the risk of  prostate cancer. For 
malignancy of  kidneys, the value of  pooled RR of  five 
case-control studies were 1.21 (95% CI=1.07-1.36), 
from 3 cohort studies were 0.45 (95% CI=0.87-2.40), 
and from the whole studies were 1.22 (95% CI=1.08-
1.37) respectively. These findings showed that the use 
of  aspirin can increase the risk of  kidney cancer. This 
result might have been due to the use of  combined 
phenacetin and aspirin (Bosetti et al., 2009).
 
Anti Cancer Mechanism of Aspirin
Aspirin acts as an anti-cancer by inhibiting 
proliferation and inducing apoptosis. Antitumor 
mechanism occurs through the barriers of  the cell cycle 
(phase G0/G1) and a shift in the balance between 
Bax/Bcl-2 (Lai et al., 2008). Aspirin activates caspase-
8, 9 and 3, as well as break down and translocate 
Bid, thereby inducing conformational changes, Bax 
Anticancer mechanism of  aspirin is also based 
on its function as an anti-platelet agent. The advance 
in science shows that platelets produce pro coagulant 
that facilitates coagulation of  cancer cells, which can be 
recruited into the tumor cells, thus protecting the cancer 
from immune response and facilitate the growth and 
spread of  cancer. This might explain the mechanism of  
aspirin as an anticancer (Bambace & Holmes, 2009).
 Aspirin also releases hydrogen sulfide (H2S), 
which will suppress NF-κB signaling in breast cancer 
cell line MDA-MB-231 ER-. Consequently, it inhibits 
cancer cell cycle in phase Go/G1, causes decreased 
activity of  thioredoxin reductase, an increased in ROS, 
induction of  apoptosis, and decreased activity of  NF-
κB. Also tumor size reduced in vivo (Chattopadhyay et 
al., 2012). The effect of  aspirin on the binding of  NF-
κB on DNA, was significantly correlated with the effect 
of  aspirin on cell growth (Williams et al., 2012).
 
Factors Influencing the Success of Aspirin Therapy
NSAIDs regular administration prior to colorectal 
cancer diagnosis is associated with improved survival of  
colorectal cancer, especially in long-term use (Coghill 
et al., 2011). Given the provision of  long-term aspirin 
treatment can prevent cancer it can be concluded that 
aspirin has two role for primary prevention. First role 
in preventing cardiovascular attacks as an anti-platelet 
aggregation, and second role is to prevent the onset 
of  cancer. The thing to note is, how to identify the 
right population, to obtain the maximum benefit with 
minimum side effects (Antonoff  & D’Cunha, 2011).
A meta-analysis showed an inverse association 
between moderate use of  NSAIDs (including aspirin) 
and colorectal cancer incidence in both men and women, 
but different types of  cancers other than colorectal 
cancer (males: HR 0.84, 95% CI=0.72-0.97; female: 
HR 1:18, 95% CI=0.97-1:44; P<0.01) in (Brasky et al., 
2012). This suggests that gender may affect the cancer 
prevention using a long-term aspirin use.
Other factors that influence the success of  
aspirin therapy were histology or type of  cancer. 
Satisfactory results have been shown in aspirin therapy 
in adenocarcinoma cancer. Some research results 
showed a less satisfactory results of  aspirin therapy 
including non-adenocarcinoma cancers (Antonoff  & 
D’Cunha, 2011). For lung cancer, the higher the success 
achieved on the type of  small-cell lung cancer compared 
with non-small cell (Khuder et al., 2005). In addition, 
the success of  cancer chemoprevention is also greater 
translocation and release of  cytochrome. Caspase-8/
Bid and Bax activation is a major role in cancer cell 
apoptosis induced by aspirin (Gu et al., 2005).
on a variety of  cells with high expression of  COX-2 
compared to COX-2 expressing little or no expression 
at all (Chan et al., 2007).
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DISCUSSIONS
Collectively, the available data showed that the 
use of  aspirin in cancer therapy may provide a new 
hope. Anticancer mechanism aspirin is based on the 
ability of  aspirin to inhibit cancer cell proliferation, 
induces apoptosis, inhibits cell cycle progression, 
signaling suppress NF-κB and its antiplatelet nature. 
The mechanism of  action enables rational therapy with 
aspirin to prevent the incidence of various types of cancer. 
The success of  cancer therapy with aspirin is influenced 
by various factors, such as the start of  therapy, gender, 
and cancer histology. Although it looks promising, it 
is worth noting that aspirin therapy has the potential 
to cause side effects that can be fatal. Therefore, most 
doctors still see the cancer risk reduction as an added 
benefit for patients requiring aspirin for the treatment 
of  disease (e.g. arthritis), not as a routine therapy aimed 
at preventing the occurrence of  cancer.
Research on the benefits of  using aspirin on a 
wide variety of  organ cancer shows a conflicting result 
both in the final outcome of  therapy and the dose and 
duration of  use. In addition, many studies have not 
been able to demonstrate the type of  patients who get 
cancer risk reduction benefits exceeding the risk of  
bleeding complications. Inconsistent results of  research 
on aspirin and other non steroidal anti-inflammatory, 
indicates the need for further research before aspirin can 
be recommended as a cancer chemopreventive agent. 
However, to avoid a risk factor for cancer is much more 
beneficial for lowering the risk of  cancer, along with the 
early detection of  cancer for those who have risk factors. 
This has proven to be the best prevention, as well as to 
decrease the number of  deaths due to cancer.
CONCLUSIONS
Aspirin gives hope as chemoprevention agent and 
cancer therapy. Factors that may affect the outcome 
of  cancer therapy with aspirin including the start of  
therapy, gender, and cancer histology. It is worth noting 
that the regular and long-term aspirin administration 
can have serious side effects, thus aspirin use has not 
been recommended for cancer prevention. The benefits 
of  aspirin as a chemoprevention is considered as an 
additional benefit for patients requiring aspirin for the 
treatment of  inflammatory diseases.
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